natgillin/translations-raw huggingface dataset:
Herudover blev observeret vægttab, diarré og/eller morbiditet, der enten var sekundære til lokale gastrointestinale påvirkninger, som følge af en høj lokal eksponering for lægemidlet i slimhinderne (aber) eller farmakologiske effekter (gnavere).
Other observed effects include body weight loss, diarrhoea and/or morbidity that were either secondary to local gastrointestinal effects caused by high local mucosal medicinal product exposure (monkeys) or pharmacologic effects (rodents).
Herudover er AUC og Cmax- værdierne for N-desmethylmetabolitten signifikant forhøjede, henholdsvis 200% og 79%.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200% and 79% respectively.
Herudover er AUC og Cmax-værdierne for N-desmethylmetabolitten signifikant forhøjede, henholdsvis 200% og 79%.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200 % and 79 % respectively.
Herudover er der blevet rapporteret om mundtørhed, der kan have en skadelig virkning på tænder og slimhinder i munden under langtidsbehandling med dette lægemiddel i kombination med et interferon alfa.
In addition, dry mouth that could have a damaging effect on teeth and membranes of the mouth has been reported during long-term treatment with this medicine in combination therapy with an alpha interferon.
Herudover er der blevet rapporteret om mundtørhed, der kan have en skadelig virkning på tænder og slimhinder i munden under langtidsbehandling med dette lægemiddel og et interferon alfa.
In addition,dry mouth that could have a damaging effect on teeth and membranes of the mouth has been reported during long-term treatment with this medicine in combination therapy with and alpha interferon.
Herudover er der rapporteret andre bivirkninger, som er kendt for at optræde i forbindelse med den kontrollerede ovarieoverstimulations-behandling (f.eks. mavesmerter, ovarieoverstimulations-syndrom (OHSS), graviditet uden for livmoderen (når fostret udvikler sig uden for livmoderen) og abort (læs indlægssedlen for det FSH-lægemiddel, du bliver behandlet med)).
In addition, side effects are reported which are known to occur with controlled ovarian hyperstimulation treatment (e.g. abdominal pain, ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy (when the embryo develops outside the womb) and miscarriage (see the patient information leaflet of the FSH-containing preparation you are treated with)).
Herudover har bivirkningsovervågning efter markedsføring af sæsonbestemte trivalente vacciner i alle aldersgrupper og med adjuverede, sæsonbestemte trivalente vacciner med lignende sammensætning som Focetria (overfladeantigen, inaktiveret, adjuveret med MF59C.1) godkendt til ældre forsøgspersoner i alderen 65 år eller derover, er der rapporteret følgende bivirkninger:
In addition, from Post-marketing surveillance with seasonal trivalent vaccines in all age groups and with the MF59 adjuvanted seasonal trivalent vaccine with the similar composition of Focetria (surface antigen, inactivated, adjuvanted with MF59C.1), licensed for use in elderly subjects above 65 years of age, the following adverse events have been reported:
Herudover har patienter oplevet: Angst, søvnløshed, næseblod, akne, udslæt, rygsmerter, uregelmæssig menstruation, blå mærker, beskadigelse af hovedet (som følge af kvæstelser under et anfald).
In addition patients have experienced: anxiety, insomnia, nose bleeds, acne, rash, back pain, infrequent periods, bruising, head injury (as a result of accidental injury during a seizure).
Herudover i Bosulif 100 mg filmovertrukne tabletter
Additionally for Bosulif 100 mg film-coated tablets
Herudover i Bosulif 500 mg filmovertrukne tabletter
Additionally for Bosulif 500 mg film-coated tablets
Herudover kan mundtørhed have en skadelig virkning på tænder og mundslimhinder under langtidsbehandling med kombinationen af IntronA og ribavirin.
In addition, dry mouth could have a damaging effect on teeth and membranes of the mouth during long-term treatment with the combination of IntronA with ribavirin.
Herudover kan mundtørhed have en skadelig virkning på tænder og mundslimhinder under langtidsbehandling med kombinationen af Viraferon og ribavirin.
In addition, dry mouth could have a damaging effect on teeth and membranes of the mouth during long-term treatment with the combination of Viraferon with ribavirin.
Herudover responderede 42 % af de eltrombopag-behandlede patienter i RAISE-studiet, med et trombocyttal ved udgangsniveau på ≤ 15.000 pr. µl, ved udgangen af den 6 måneders behandlingsperiode.
In addition, in the RAISE study, 42% of patients with baseline platelet count ≤ 15,000/μl treated with eltrombopag responded at the end of the 6 month treatment period.
Herudover testede 6 % af de pædiatriske patienter i en undersøgelse seropositive mindst én gang i løbet af undersøgelsen for antistoffer, der var i stand til at neutralisere de biologiske effekter af anakinra.
In addition, in a clinical trial 6% of paediatric patients tested seropositive at least once during the study for antibodies capable of neutralising the biologic effects of anakinra.
Herudover viste perifere blodlymfocytter intet signifikant fald i antal eller i proliferativt respons af in vitro mitogenisk stimulation sammenlignet med ubehandlede patienters celler.
Peripheral blood lymphocytes further showed no significant decrease in number or in proliferative responses to in vitro mitogenic stimulation when compared with untreated patients’ cells.
Herunder (men ikke udelukkende):
These include (but are not limited to):
Herunder gives en kort anvisning i, hvordan Rebif cylinderampuller anvendes med hvert apparat.
Short instructions on how to use Rebif cartridges with each device are given below.
herunder nyrerelaterede
Darunavir:
Herunder observationer, som var indsamlet som en del af rutinemæssig laboratorie-overvågning
4 Includes observations collected as part of routine laboratory monitoring.
Herved bliver faktor VIII mindre virkningsfuld til at kontrollere blødninger.
This makes factor VIII less effective in controlling bleeding.
Herved sænkes blodsukkeret som er for højt, når man har type 2-sukkersyge.
This helps to lower blood sugar levels, which are too high in patients with type 2 diabetes.
Herved vil medicinpulveret og væsken i den gennemsigtige cylinderampul blive blandet.
This will mix the medicine powder and liquid in the clear cartridge.
Hest
Equidae
Hest
Horse
hest
Horses
Hest
Horses.
Hest.
Horses
Hest: i.v.
Horses: IV
Hest: Intravenøs brug.
Horses: Intravenous use.
Hest: Intravenøs injektion.
Horses: Intravenous use
Hest: se afsnit 5. ”Kontraindikationer”.
Horses: See section "Contraindications".
Hest: Slagtning: 5 døgn
Horses: meat and offal: 5 days
Hest: Slagtning: 5 døgn.
Horses: Meat and offal: 5 days.
Heste bør have en basisvaccination ved 5-6 måneders alderen bestående af to vaccinationer med 4 - 6 ugers mellemrum.
Horses should receive a primary vaccination, consisting of two injections at 5–6 months of age, given 4–6 weeks apart.
Heste bør have en basisvaccination ved 5-6 måneders alderen bestående af to vaccinationer med 4-6 ugers
Horses should receive a primary vaccination, consisting of two injections at 5–6 months of age, given 4–6 weeks apart.
Heste, der skal bruges til væddeløb og konkurrencer, skal behandles i overensstemmelse med lokale retningslinjer, og der skal træffes passende foranstaltninger til at sikre overholdelse af de officielle konkurrenceregler.
Horses intended for racing and competition should be treated according to local requirements and appropriate precautions must be taken to ensure compliance with the official competition regulations.
Heste.
6.
Heste: Enkelt i.v. injektion.
Horses: Single I.V. injection.
Heste: i.v. injektion.
Horses: IV injection.
Heste: intravenøs anvendelse
Horses: intravenous use
Heste: intravenøs brug
Horses: intravenous use
Heste: kød og indmad: 5 dage
Horses: meat and offal: 5 days
Heste: kød og indmad: 5 dage
Horses: meat and offal: 5 days.
Heste: Kød og indmad: 5 dage
Meat and offal: 5 days
Heste: kød og indmad: 5 dage.
Horses: meat and offal: 5 days.
Heste: Kød og slagteaffald: 5 dage
Horses: meat and offal: 5 days
Heste: Må ikke anvendes til drægtige eller lakterende hopper (se afsnit 4.3).
Horses: Do not use in pregnant or lactating mares (see section 4.3).
Heste: Må ikke anvendes til drægtige eller lakterende hopper (se afsnittet ’Kontraindikationer’).
Horses: Do not use in pregnant or lactating mares (see section “Contraindications”).
Heste: Må ikke anvendes til drægtige eller lakterende hopper.
Horses: Do not use in pregnant and lactating mares.
Heste: Se afsnittet ’Kontraindikationer’
Horses: See section "Contraindications".
Heste: Se afsnittet ’Kontraindikationer’.
Horses: See section "Contraindications".
Heste:Kød og indmad: 5 dage.
Horses: Meat and offal: 5 days.
Hesten bør derfor overvåges hyppigt i behandlingsperioden.
Therefore horses should be monitored frequently during the treatment period.
Hestenes reaktion på behandlingen blev bedømt på forbedringen i særlige kliniske score-værdier for hver af de undersøgte lidelser.
The response of the horses to treatment was measured using the improvement in specific clinical scores for each condition studied.
Het aantal patiënten dat een co-primair eindpunt bereikte (CV overlijden, MI, CVA of refractaire ischemie), was 1035 (16,5%) in de groep behandeld met clopidogrel en 1187 (18,8%) in de groep behandeld met placebo; dit is een relatieve risicoreductie van 14% (95% CI van 6%-21%, p = 0,0005) voor de groep behandeld met clopidogrel.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Het aantal patiënten dat een primair eindpunt bereikte [cardiovasculair (CV) overlijden, myocardinfarct (MI), of CVA] was 582 (9,3%) in de groep behandeld met clopidogrel en 719 (11.4%) in de groep behandeld met placebo; dit is een relatieve risicoreductie van 20% (95% CI van 10%-28%; p = 0.00009) voor de groep behandeld met clopidogrel (een relatieve risicoreductie van 17 % werd vastgesteld wanneer de patiënten op een conservatieve wijze werden behandeld, wanneer zij een percutane transluminale coronaire angioplastie (PTCA) met of zonder stent ondergingen was dat 29 % en wanneer zij een coronaire arteriële bypass graft (CABG) ondergingen was dit 10 %).
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Het aantal patiënten dat het primaire eindpunt (tijd tot het eerste optreden van een CVA, MI, niet-CZS systemische embolie of vasculair overlijden) bereikte, was 832 (22,1%) in de groep behandeld met clopidogrel + ASA en 924 (24,4%) in de placebo + ASA groep (relatieve risicoreductie van 11,1%; 95% CI van 2,4% tot 19,1%; p=0,013), voornamelijk te wijten aan een grote reductie van de incidentie van CVA.
+ ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes.
Het CYP2C19*1-allel correspondeert met een volledig functioneel metabolisme, terwijl de CYP2C19*2- en CYP2C19*3-allelen niet-functioneel zijn.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
Het gebruik van clopidogrel in de CURE-studie was geassocieerd met een vermindering van de noodzaak van een trombolytische behandeling (RRR = 43,3 %; CI: 24,3 %, 57,5 %) en van GPIIb/IIIa antagonisten (RRR = 18,2 %; CI: 6,5 %, 28,3 %).
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Het is aanbevolen om patiënten met een voorgeschiedenis van allergie voor thiënopyridines te controleren op verschijnselen van overgevoeligheid.
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised.
Het is evenwel op dit moment niet duidelijk of er bij alle NSAID's een verhoogd risico op gastro-intestinale bloedingen bestaat, omdat interactiestudies met andere NSAID's ontbreken.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Het is niet bekend of clopidogrel wordt uitgescheiden in de moedermelk bij de mens.
It is unknown whether clopidogrel is excreted in human breast milk.
Het is onwaarschijnlijk dat uw rijvaardigheid of uw vermogen om machines te gebruiken door Zyllt wordt beïnvloed.
Zyllt is unlikely to affect your ability to drive or to use machines.
Het is te verwachten dat esomeprazol een vergelijkbare interactie vertoont met clopidogrel.
Esomeprazole is expected to give a similar interaction with clopidogrel.
Het melden van bijwerkingen
Reporting of side effects
Het wordt aanbevolen om dit geneesmiddel tijdens de zwangerschap niet in te nemen.
It is preferable not to take this medicine during pregnancy.
Heterakis gallinarum (L5 og voksne stadier)
Heterakis gallinarum (L5 and adult stages)
Heterakis gallinarum (L5 og voksne stadier)
Heterakis gallinarum (L5 and adult stages).
Heterologt immunrespons mod A/H5N1/Indonesia/5/05 (clade 2.1) kunne måles i Studie V87P11 efter den anden vaccination, hvilket tyder på krydsreaktivitet for clade 2.2 vaccinen mod clade 2.1 stammerne.
Heterologous immune response against A/H5N1/Indonesia/5/05 (clade 2.1) was detectable in study V87P11 after the second vaccination, indicating cross-reactivity of the clade 2.2 vaccine against clade 2.1 strains.
Heterotop ossifikation1,3*
Heterotopic ossification1, 3
heterotopisk ossifikation af det omgivende væv
heterotopic ossification of the surrounding tissues
Hexacima beskytter ikke mod hepatitisinfektion, der stammer fra andre smitsomme organismer, f.eks. hepatitis A, hepatitis C og hepatitis E eller andre, der angriber leveren.
Hexacima will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E.
Hexacima gives som en injektion ind i en muskel (intramuskulært, IM) i den øverste del af barnets ben eller overarm.
Hexacima is given as an injection into a muscle (intramuscular route IM) in the upper part of your child’s leg or upper arm.
Hexacima gives til børn i alderen fra seks uger.
Hexacima is given to children from six weeks of age.
Hexacima hjælper kun med at forebygge disse sygdomme, hvis de stammer fra de bakterier eller virus, som denne vaccine er rettet imod.
Hexacima will only help to prevent these diseases if they are caused by the bacteria or viruses targeted by the vaccine.
Hexacima hjælper med at beskytte mod difteri, stivkrampe, kighoste, leverbetændelse B, polio og alvorlige sygdomme, der stammer fra Haemophilus influenzae type b.
Hexacima helps to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b.
Hexacima injektionsvæske, suspension DTaP-IPV-HBV-Hib
Hexacima suspension for injection DTaP-IPV-HB-Hib
Hexacima injektionsvæske, suspension i fyldt injektionssprøjte
Hexacima suspension for injection in pre-filled syringe
Hexacima kan gives samtidigt med andre vacciner, f.eks. pneumokok-vacciner, MFR-vacciner (mod mæslinger, fåresyge og røde hunde), rotavirus-vacciner og meningokok-vacciner.
Hexacima can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella vaccines, rotavirus vaccines or meningococcal vaccines.
Hexacima kan gives samtidigt med andre vacciner, f.eks. pneumokok-vacciner, MFR-vacciner (mod mæslinger, fåresyge og røde hunde), rotavirus-vacciner og meningokokvacciner.
Hexacima can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella vaccines, rotavirus vaccines or meningococcal vaccines.
Hexacima må ikke blandes med andre lægemidler.
Hexacima should not be mixed with other medicinal products.
Hexacima skal administreres intramuskulært.
Hexacima must be administered intramuscularly.
Hexacima – Karton til fyldt injektionssprøjte uden nål, med én separat nål, med to separate nåle.
Hexacima – Carton for pre-filled syringe without needle, with one separate needle, with two separate needles.
Hexacima – Karton til hætteglas.
Hexacima – Carton for vial.
Hexal AG, Industriestrasse 25, D-83607 Holzkirchen, Tyskland
Hexal AG, Industriestrasse 25, D-83607 Holzkirchen, Germany
HEXAVAC bør ikke anvendes ved fødslen eller efterfølgende vaccinationer i løbet af det første leveår til børn født af HBsAg-positive mødre.
HEXAVAC should not be used as the birth dose or subsequent doses during the first year of life for children born to HbsAg- positive mothers.
HEXAVAC injektionsvæske, suspension i fyldt injektionssprøjte
HEXAVAC suspension for injection in pre-filled syringe
HEXAVAC kan anvendes til booster dosen forudsat at det lille barn har fået et fuldstændigt grundvaccinationsprogram for hvert antigen indeholdt i HEXAVAC, uanset om de blev administreret som en monovalent eller en kombinationsvaccine fremstillet af Sanofi Pasteur MSD.
HEXAVAC can be used for the booster dose provided the toddler has received a full primary vaccination course of each of the antigens contained in Hexavac regardless of whether they were administered as monovalent or combination vaccines produced by Sanofi Pasteur MSD.
HEXAVAC skal administreres intramuskulært i quadriceps eller deltoidmusklen, fortrinsvis på skiftende injektionssteder ved efterfølgende injektioner.
HEXAVAC should be administered intramuscularly into the quadriceps or deltoid preferably at alternating sites for subsequent injections.
Hexyon beskytter ikke mod hepatitisinfektion, der stammer fra andre smitsomme organismer, f.eks. hepatitis A, hepatitis C og hepatitis E eller andre, der angriber leveren.
Hexyon will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E.
Hexyon gives som en injektion ind i en muskel (intramuskulært, IM) i den øverste del af barnets ben eller overarm.
Hexyon is given as an injection into a muscle (intramuscular route IM) in the upper part of your child’s leg or upper arm.
Hexyon gives til børn i alderen fra seks uger.
Hexyon is given to children from six weeks of age.
Hexyon hjælper kun med at forebygge disse sygdomme, hvis de stammer fra de bakterier eller virus, som denne vaccine er rettet imod.
Hexyon will only help to prevent these diseases if they are caused by the bacteria or viruses targeted by the vaccine.
Hexyon hjælper med at beskytte mod difteri, stivkrampe, kighoste, leverbetændelse B, polio og alvorlige sygdomme, der stammer fra Haemophilus influenzae type b.
Hexyon helps to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b.
Hexyon i fyldte injektionssprøjter
Hexyon in pre-filled syringes EU/1/13/829/002 EU/1/13/829/003 EU/1/13/829/004 EU/1/13/829/005
Hexyon injektionsvæske, suspension DTaP-IPV-HBV-Hib
Hexyon suspension for injection DTaP-IPV-HB-Hib
Hexyon injektionsvæske, suspension i fyldt injektionssprøjte
Hexyon suspension for injection in pre-filled syringe
Hexyon kan gives samtidigt med andre vacciner, f.eks. pneumokok-vacciner, MFR-vacciner (mod mæslinger, fåresyge og røde hunde), rotavirus-vacciner og meningokok-vacciner.
Hexyon can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella vaccines, rotavirus vaccines or meningococcal vaccines.
Hexyon kan gives samtidigt med andre vacciner, f.eks. pneumokok-vacciner, MFR-vacciner (mod mæslinger, fåresyge og røde hunde), rotavirus-vacciner og meningokokvacciner.
Hexyon can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella vaccines, rotavirus vaccines or meningococcal vaccines.
Hexyon må ikke blandes med andre lægemidler.
Hexyon should not be mixed with other medicinal products.
Hexyon skal administreres intramuskulært.
Hexyon must be administered intramuscularly.
Hexyon – Pakning med fyldt injektionssprøjte med to separate nåle.
Hexyon – Carton for pre-filled syringe with two separate needles.
Hexyon – Pakning med fyldt injektionssprøjte med én separat nål.
Hexyon – Carton for pre-filled syringe with one separate needle.
Hexyon – Pakning med fyldt injektionssprøjte uden nål.
Hexyon – Carton for pre-filled syringe without needle.
Hexyon – Pakning til hætteglas.
Hexyon – Carton for vial.
Hgb-ændring fra baseline på dag 35 (Mean ± SD, g/dl)
Hgb change from Baseline at Day 35 (mean ± SD, g/dl)
Hhjælpestoffer
List of excipients
HI titer ≥
HI titre ≥
Hib til Infanrix hexa
Hib for Infanrix hexa
Hib- komponenten har også været tilgængelig i andre vacciner.
The Hib component has also been available in other vaccines.
Hib-komponenten er et hvidt pulver, som leveres i et hætteglas.
The Hib component is a white powder presented in a glass vial.
Hib-pulver: Vandfri lactose
Hib powder: Lactose anhydrous
Hidtil ubehandlede patienter
Previously untreated patients
High density polyethylene flaske, polypropylen- doseringssprøjte
HDPE bottle polypropylene measuring syringe
High-density polyethylen (HDPE) beholdere produceret med propylen-hætter.
High density polyethylene (HDPE) bottles closed with propylene caps.
High-density polyethylen (HDPE) flaske med børnesikret polypropylenlåg.
High-density polyethylene (HDPE) bottle with a polypropylene child-resistant closure.
High-density polyethylen (HDPE) flasker produceret med propylen hætter.
High density polyethylene (HDPE) bottles closed with propylene caps.
High-density polyethylen flaske indeholdende 100ml eller 250 ml med børnesikret lukning, og en polyethylen doseringssprøjte.
HDPE bottle containing 100 or 250 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.
High-RiSk AcUte Coronary Syndrome Patients]-studiet, en sammenligning mellem ticagrelor kombineret med ASA og ASA-behandling alene.
High-RiSk AcUte Coronary Syndrome Patients] study, a comparison of ticagrelor combined with ASA to ASA therapy alone.
Hikke
Hiccups
hikke punkteret lunge, hvor luften bliver fanget mellem lungen og brystet, hvilket ofte forårsager åndenød (pneumothorax)
hiccups lung collapses and air gets trapped in the space between the lung and chest, often causing shortness of breath (pneumothorax)
hikke, bøvsning
hiccups, burping
hikke, forandret stemme
hiccups, change in voice
Hikke, luft i maven, tør mund eller fordøjelsesbesvær
hiccups, flatulence, dry mouth or indigestion
Hikke, pharyngolaryngeal smerte, dysfoni
+Febrile Neutropenia
hikke, stemmeændringer
hiccups, change in voice
Hikke, taleforstyrrelser
Hiccups, speech disorders
hikke, tør mund.
hiccups, dry mouth.
hikke, ændret stemme,
hiccups, change in voice
Hikkee
Hiccupse
Hillerød, DK-3400 Danmark
Hillerød, DK-3400 Denmark
Hipersensibilidad al principio activo o a alguno de los excipientes.
Hypersensitivity to the active substance or to any of the excipients.
Hiprabovis IBR Marker Live er en vaccine, der indeholder en IBR-virus, som er blevet genetisk modificeret for at fjerne to gener og dermed gøre den mindre ”patogen” (dvs. begrænse dens evne til
Hiprabovis IBR Marker Live is a vaccine that contains an IBR virus that has been genetically modified to delete two genes so that the virus is less ‘pathogenic’ (less able to cause a disease).
HIPRABOVIS IBR MARKER LIVE, lyofilisat og solvens til injektionsvæske, suspension, til kvæg.
HIPRABOVIS IBR MARKER LIVE lyophilisate and solvent for suspension for injection for cattle.
HIPRABOVIS IBR MARKER LIVE, lyofilisat til injektionsvæske, suspension.
HIPRABOVIS IBR MARKER LIVE lyophilisate for suspension for injection.